Late-stage immunology research programs
AbbVie (ABBV) is rapidly advancing registrational programs for its late-stage immunology assets upadacitinib and risankizumab for the treatment of rheumatoid arthritis (or RA) and psoriasis, respectively.
Risankizumab and upadacitinib research programs
AbbVie plans to file a new drug application (or NDA) for risankizumab in a plaque psoriasis indication in 1H18. Based on results from four pivotal trials in the risankizumab Phase 3 program, the company expects the investigational drug to prove a more effective and highly durable treatment option for moderate to severe psoriasis patients who are naïve to biological therapy as well as for those patients who are inadequate responders to tumor necrosis factor (or TNF) inhibitors such as Humira, Amgen’s (AMGN) Enbrel, Johnson & Johnson’s (JNJ) Enbrel, or Pfizer’s (PFE) biosimilar referencing Remicade, Inflectra.
Risankizumab can also improve on existing psoriasis regimens by offering patients a more convenient quarterly dosing treatment option. To learn more about the progress of the risankizumab research program for the treatment of psoriasis, read Risankizumab Expected to Emerge as a Robust treatment Option for Psoriasis Patients.
AbbVie is also exploring risankizumab’s potential in other immunology indications, such as for the treatment of psoriatic arthritis, ulcerative colitis, and Crohn’s disease. To learn more about AbbVie’s label expansion initiatives for risankizumab, read Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications.
AbbVie also has another immunology asset in its late-stage research programs: the selective JAK1 inhibitor upadacitinib. This oral therapy is being currently evaluated in six indications across therapeutic areas such as gastrointestinal disorders, rheumatology, and dermatology. To learn more about the SELECT-NEXT trial’s results, read What Upadacitinib Did for AbbVie in 2017. To learn more about the SELECT-MONOTHERAPY trial’s results, read Why AbbVie’s Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis.
AbbVie expects to see data from two more pivotal trials evaluating upadacitinib in a rheumatoid arthritis (or RA) indication in 1H18, while the company expects to file regulatory applications in 2H18. The company expects upadacitinib to prove to be a best-in-class therapy in an RA indication.
In the next article, we’ll discuss AbbVie’s oncology drug, Imbruvica, in greater detail.